NKT cells with an invariant T cell receptor a chain (iNKT cells) are a unique T cell sublineage capable of rapidly producing an array of cytokines when activated through their TCR. In mouse model systems, they have been reported to exert a pivotal role in determining the outcome of a variety of immune responses and pathologic conditions, including the development of autoimmunity, the maintenance of self-tolerance, the response to tumors and infectious agents, and even atherosclerosisdevelopment. Moreover, cancer immune therapy clinical trials based on activating iNKT cells have been carried out. iNKT cells are autoreactive for antigens presented by CD1d and their specificity is highly conserved when mouse and human are compared. Until recently, however, it was not known what glycolipids presented by CD1d were the natural antigens that activate iNKT cells, and their reactivity for microbial antigens was controversial. Our preliminary data establish that the majority of iNKT cells are reactive to several categories of bacterial glycolipids that have a terminal, a-linked hexose sugar, and that this reactivity is likely to be responsible for protective immune responses. We propose to apply an array of biochemical and immunological techniques, ranging from in vitro TCR binding studies to measurements of immune responses in vivo, in order to understand how bacterial glycolipids are recognized, and how the response to them mediates host protection. Therefore, these studies will provide important information on the basic biology of iNKT cells and their physiologic raison d'etre, including their ability to recognize antigens, the forces driving their selection and conservation, and their participation in host protection, and they may lead to improved vaccines against bacterial pathogens. ;

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI045053-08
Application #
7324064
Study Section
Special Emphasis Panel (ZRG1-IHD (01))
Program Officer
Miller, Lara R
Project Start
2000-04-15
Project End
2010-11-30
Budget Start
2007-12-01
Budget End
2008-11-30
Support Year
8
Fiscal Year
2008
Total Cost
$361,588
Indirect Cost
Name
La Jolla Institute
Department
Type
DUNS #
603880287
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Chandra, Shilpi; Gray, James; Kiosses, William B et al. (2018) Mrp1 is involved in lipid presentation and iNKT cell activation by Streptococcus pneumoniae. Nat Commun 9:4279
Sag, Duygu; Özkan, Müge; Kronenberg, Mitchell et al. (2017) Improved Detection of Cytokines Produced by Invariant NKT Cells. Sci Rep 7:16607
Wingender, Gerhard; Birkholz, Alysia M; Sag, Duygu et al. (2015) Selective Conditions Are Required for the Induction of Invariant NKT Cell Hyporesponsiveness by Antigenic Stimulation. J Immunol 195:3838-48
Birkholz, Alysia M; Girardi, Enrico; Wingender, Gerhard et al. (2015) A Novel Glycolipid Antigen for NKT Cells That Preferentially Induces IFN-? Production. J Immunol 195:924-33
Birkholz, Alysia; Nem?ovi?, Marek; Yu, Esther Dawen et al. (2015) Lipid and Carbohydrate Modifications of ?-Galactosylceramide Differently Influence Mouse and Human Type I Natural Killer T Cell Activation. J Biol Chem 290:17206-17
Engel, Isaac; Kronenberg, Mitchell (2014) Transcriptional control of the development and function of V?14i NKT cells. Curr Top Microbiol Immunol 381:51-81
Sag, Duygu; Krause, Petra; Hedrick, Catherine C et al. (2014) IL-10-producing NKT10 cells are a distinct regulatory invariant NKT cell subset. J Clin Invest 124:3725-40
Thakur, Meena S; Khurana, Archana; Kronenberg, Mitchell et al. (2014) Synthesis of a 2""-deoxy-?-GalCer. Molecules 19:10090-102
Kinjo, Yuki; Kitano, Naoki; Kronenberg, Mitchell (2013) The role of invariant natural killer T cells in microbial immunity. J Infect Chemother 19:560-70
Kawasaki, Norihito; Vela, Jose Luis; Nycholat, Corwin M et al. (2013) Targeted delivery of lipid antigen to macrophages via the CD169/sialoadhesin endocytic pathway induces robust invariant natural killer T cell activation. Proc Natl Acad Sci U S A 110:7826-31

Showing the most recent 10 out of 55 publications